As adoption accelerates, insurers are discovering that generic artificial intelligence (AI) tools can carry hidden costs, governance gaps and integration risks. The critical question is whether the platform you choose is truly AI-native or merely AI-augmented, writes Will Watling
Across the UK and EU, life insurers are waking up to an uncomfortable discovery: the AI platforms they invested in during proof of concept may be punishing them in production. Governance gaps can leave firms exposed to regulatory scrutiny. Token costs can spiral and integration architectures designed for a pre-agentic world are accumulating technical debt. The root of the problem is straightforward. Most solutions on the market are general-purpose AI tools dressed up with an insurance label, never designed for long-duration obligations, strict regulatory oversight or financial exposur...
To continue reading this article...
Join Professional Adviser for free
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes




